Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results and Recent Operational Highlights
Date:10/31/2011

MALVERN, Pa., Oct. 31, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended September 30, 2011. For the third quarter of 2011, Auxilium reported net revenues of $66.7 million compared to net revenues of $53.6 million in the third quarter of 2010.  The net loss for the third quarter of 2011 was $(4.1) million, or $(0.08) per share, compared to a net loss of $(12.8) million, or $(0.27) per share, reported for the third quarter of 2010.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

"We believe that the progress we made in the third quarter of 2011 will drive long term shareholder value.  XIAFLEX® revenues showed sequential growth over the second quarter of 2011, despite a slight decrease in overall Dupuytren's procedure volumes, and new XIAFLEX data were well received by physicians attending the American Society for Surgery of the Hand meeting.  We remain encouraged by the physician and patient success stories and believe that XIAFLEX will become the standard of care for Dupuytren's contracture," said Armando Anido, Chief Executive Officer and President of Auxilium.  "Testim® continued to perform well, despite continuing competition in the testosterone replacement market, with prescriptions posting growth over the third quarter of 2010 and over the second quarter 2011."  

Third Quarter and Recent Operational Highlights: XIAFLEX:

  • Worldwide net revenues for XIAFLEX were $13.1 million for the third quarter 2011, up 130% versus the third quarter of 2010.
  • Net revenues of XIAFLEX in the U.S. were $10.3 million in the third quarter 2011, up 124% versus the third quarter of 2010.  
  • At the 2011 ASSH meeting in early September, physician attendees expresse
    '/>"/>

  • SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update
    2. Auxilium Pharmaceuticals to Present at the Morgan Stanley 2011 Healthcare Conference
    3. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
    4. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
    5. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
    6. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
    7. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
    8. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
    9. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
    10. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
    11. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... ST. LOUIS , Dec. 23, 2014 /PRNewswire/ ... announced today that the waiting period under the ... with the acquisition expired on December 22, 2014, ... and review requirement for the acquisition of the ... U.S. antitrust clearance satisfies another condition to ...
    (Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
    (Date:12/22/2014)... December 22, 2014 ITRA Global, one ... occupiers of commercial real estate, has further expanded its ... in Perth and Brisbane, Western Australia, reports Mylinda Vick, ... , ITRA Global / ACORPP (Australian Corporate Property ... consultancy company providing property services to a wide range ...
    (Date:12/19/2014)... 2014 Naurex Inc., a biopharmaceutical company leveraging ... of the central nervous system, today announced that ... will present at the 33 rd annual J.P. ... at 3:00 p.m. PST on Tuesday, January 13, 2015, ... Francisco, Calif. About Naurex ...
    Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
    ... today announced,that researchers will present eight abstracts ... Meeting of the American Thoracic Society, from ... Presentations are designed to showcase,MedImmune,s biologics capabilities., ... solutions that may one,day help patients struggling ...
    ... Novasys Medical, Inc., a,developer of innovative therapies ... $49.5 million in Series D preferred stock financing. ... Partners and Skyline,Ventures also participating as new investors. ... Capital Management, Alloy,Ventures, Delphi Ventures, GBS Venture Partners, ...
    ... Revenues Increase Over 29% From Previous Quarter, ... (OTC:,SPOM), a leading developer of biosensor and microprocessor ... first quarter results for,the period ended March 31, ... US$1,079,000, a 29% increase over,fourth quarter 2007 gross ...
    Cached Biology Technology:Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society 2Novasys Medical Secures $49.5 Million in Series D Financing to Expand Commercialization of Its Renessa(R) Treatment for Incontinence in Women 2SPO Medical Reports First Quarter 2008 Results 2SPO Medical Reports First Quarter 2008 Results 3
    (Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
    (Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
    (Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
    Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
    ... additional brush strokes to the revolutionary new image now emerging ... cord. Their report, which suggests a key role for astrocytes ... online in ACS, Journal of Proteome Research , a ... point out that nearly everyone viewed astrocytes the most ...
    ... from The University of Alabama used worms to reel in ... of cellular mechanisms that may be exploited to treat epilepsy. ... ( http://www.genetics.org ), the researchers explain how the transparent ... switches" that control the transport of a molecule (gamma-aminobutyric acid ...
    ... taint" smell in the meat and allows them to contain ... different. Now, for the first time, a scientific team has ... The main conclusion of the study, that forms part of ... by the livestock farmers, without anaesthetic and in some cases, ...
    Cached Biology News:More than fish bait: Worms unlock secrets to new epilepsy treatments 277 percent of European pigs are castrated without anesthetic 2
    Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Antigen: Synthetic peptide corresponding to...
    Polyclonal Antibody to TRIB1/ SKIP1/ Tribbles 1...
    TNF-Related Apoptosis Inducing Ligand-Receptor-1...
    PMA (YPMA-1)...
    Biology Products: